In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569

Behavioural Pharmacology

Volumn 25, Issue 2, 2014, Pages 182-185

  Gamage, Thomas F ^a   Ignatowska Jankowska, Bogna M ^a   Wiley, Jenny L ^b   Abdelrahman, Mostafa ^c   Trembleau, Laurent ^c   Greig, Iain R ^c   Thakur, Ganesh A ^d   Tichkule, Ritesh ^d   Poklis, Justin ^a   Ross, Ruth A ^c,e   Pertwee, Roger G ^c   Lichtman, Aron H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d NORTHEASTERN UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

a940; allosteric modulator; anandamide; cannabinoid; CP55; mouse; rimonabant

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR AFFECTING AGENT; ORG 27569; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; 5-CHLORO-3-ETHYL-1H-INDOLE-2-CARBOXYLIC ACID (2-(4-PIPERIDIN-1-YL-PHENYL)ETHYL)AMIDE; AMIDASE; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXANOL DERIVATIVE; DRONABINOL; ENDOCANNABINOID; FATTY-ACID AMIDE HYDROLASE; INDOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ALLOSTERISM; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG BRAIN LEVEL; DRUG SCREENING; FEMALE; FOOD INTAKE; HYPOTHERMIA; INVERSE AGONISM; MALE; MOUSE; NONHUMAN; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; EATING; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; KNOCKOUT MOUSE; METABOLISM; NOCICEPTION; PHYSIOLOGY;

ALLOSTERIC REGULATION; AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOID RECEPTOR MODULATORS; CATALEPSY; CYCLOHEXANOLS; DRONABINOL; DRUG EVALUATION; EATING; ENDOCANNABINOIDS; FEMALE; HYPOTHERMIA; INDOLES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, KNOCKOUT; NOCICEPTION; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 84896359609     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000027     Document Type: Article

References (15)

1. Ahn KH, Mahmoud MM, Kendall DA (2012). Allosteric modulator ORG27569 induces a CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization and Gi-independent ERK1/2 activation. J Biol Chem 287:12070-12082.
2. Ahn KH, Mahmoud MM, Shim J-Y, Kendall DA (2013). Distinct roles of b-arrestin 1 and b-arrestin 2 in Org27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J Biol Chem 288:9790-9800.
3. Baillie GL, Horswill JG, Anavi-Goffer S, Reggio PH, Bolognini D, Abood ME, et al. (2013). CB1 receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol 83:322-338.
4. Bauer M, Chicca A, Tamborrini M, Eisen D, Lerner R, Lutz B, et al. (2012). Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem 287:36944-36967.
5. Cawston EE, Redmond WJ, Breen C, Grimsey N, Connor M, Glass M (2013). Real-time characterisation of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action. Br J Pharmacol 170: 893-907.
6. Di Marzo V, Matias I (2005). Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589.
7. Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH, et al. (2010). FAAH-/-mice display differential tolerance, dependence, and cannabinoid receptor adaptation after D9-tetrahydrocannabinol and ananda-mide administration. Neuropsychopharmacology 35:1775-1787.
8. Horswill J, Bali U, Shaaban S, Keily J, Jeevaratnam P, Babbs A, et al. (2007). PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 152:805-814.
9. Ignatowska-Jankowska B, Ghosh S, Crowe M, Kinsey S, Niphakis M, Abdullah R, et al. (2013). In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol doi: 10.1111/bph.12298. [Epub ahead of print].
10. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, et al. (2009). Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330:902-910.
11. Navarro HA, Howard JL, Pollard GT, Carroll F (2009). Positive allosteric modulation of the human cannabinoid (CB1) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol 156: 1178-1184.
12. Pamplona FA, Ferreira J, de Lima OM, Duarte FS, Bento AF, Forner S, et al. (2012). Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci USA 109:21134-21139.
13. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, et al. (2005). Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68:1484-1495.
14. Resources IoLA (2011). Guide for the care and use of laboratory animals. Washington, DC: Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council.
15. Ross RA (2007). Allosterism and cannabinoid CB1 receptors: the shape of things to come. Trends Pharmacol Sci 28:567-572.